Amirali Karimi

Amirali Karimi

Auto-generated profile, based on publicly available information

Amirali Karimi

School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
EMEsmaeil Mehraeen
Esmaeil Mehraeen
AKAmirali Karimi
Amirali Karimi
ABAlireza Barzegary
Alireza Barzegary
FVFarzin Vahedi
Farzin Vahedi
AAAmir Masoud Afsahi
Amir Masoud Afsahi
SJShayesteh Jahanfar
Shayesteh Jahanfar

9 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
TSTahereh Soltantoyeh
Tahereh Soltantoyeh
BABehnia Akbari
Behnia Akbari
AKAmirali Karimi
Amirali Karimi
GGhanbar Mahmoodi Chalbatani
Ghanbar Mahmoodi Chalbatani
NGNavid Ghahri-Saremi
Navid Ghahri-Saremi
HMHamed Mirzaei
Hamed Mirzaei
Metastatic melanoma is the most aggressive and difficult to treat type of skin cancer, with a survival rate of less than 10%. Metastatic melanoma has conventionally been considered very difficult to treat; however, recent progress in understanding the cellular and molecular mechanisms involved in the tumorigenesis, metastasis and immune escape have led to the introduction of new therapies. These include targeted molecular therapy and novel immune-based approaches such as immune checkpoint blockade (ICB), tumor-infiltrating lymphocytes (TILs), and genetically engineered T-lymphocytes such as chimeric antigen receptor (CAR) T cells. Among these, CAR T cell therapy has recently made promising strides towards the treatment of advanced hematological and solid cancers. Although CAR T cell therapy might offer new hope for melanoma patients, it is not without its shortcomings, which include off-target toxicity, and the emergence of resistance to therapy (e.g., due to antigen loss), leading to eventual relapse. The present review will not only describe the basic steps of melanoma metastasis, but also discuss how CAR T cells could treat metastatic melanoma. We will outline specific strategies including combination approaches that could be used to overcome some limitations of CAR T cell therapy for metastatic melanoma.

20 May 2021 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
SSSeyedAhmad SeyedAlinaghi
SeyedAhmad SeyedAlinaghi
MMMohammad Mehrtak
Mohammad Mehrtak
MMMehrzad MohsseniPour
Mehrzad MohsseniPour
PMPegah Mirzapour
Pegah Mirzapour
ABAlireza Barzegary
Alireza Barzegary
FVFabricio Voltarelli
Fabricio Voltarelli
Introduction: While COVID-19 pandemic continues to spread worldwide, researchers have linked patterns of traits to poor disease outcomes. Risk factors for COVID-19 include asthma, elderly age, being pregnant, having any underlying diseases such as cardiovascular disease, diabetes, obesity, and experiencing lifelong systemic racism. Recently, connections to certain genes have also been found, although the susceptibility has not yet been established. We aimed to investigate the available evidence for the genetic susceptibility to COVID-19. Methods: This study was a systematic review of current evidence to investigate the genetic susceptibility of COVID-19. By systematic search and utilizing the keywords in the online databases including Scopus, PubMed, Web of Science, and Science Direct, we retrieved all the related papers and reports published in English from December 2019 to September 2020. Results: According to the findings, COVID-19 uses the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry. Previous studies have shown that people with ACE2 polymorphism who have type 2 transmembrane serine proteases (TMPRSS2) are at high risk of SARS-CoV-2 infection. Also, two studies have shown that males are more likely to become infected with SARS-CoV-2 than females. Besides, research has also shown that patients possessing HLA-B*15:03 genotype may become immune to the infection. Conclusion: Combing through the genome, several genes related to immune system’s response were related to the severity and susceptibility to the COVID-19. In conclusion, a correlation was found between the ACE2 levels and the susceptibility to SARS-CoV-2 infection.

1 November 2020 in Indian Heart Journal
Verified
Journal Article
Open access
EMEsmaeil Mehraeen
Esmaeil Mehraeen
SSSeyedAhmad SeyedAlinaghi
SeyedAhmad SeyedAlinaghi
ANAli Nowroozi
Ali Nowroozi
Omid DadrasOmid Dadras
Omid Dadras
SASanam Alilou
Sanam Alilou
AKAmirali Karimi
Amirali Karimi
Since the epidemic of COVID-19 attractedthe attention, reports were surrounding electrocardiographic changes in the infected individuals. We aimed at pinpointing different observed ECG findings and discussing their clinical significance. We conducted a systematic search in PubMed, Embase, and Scopus databases. We included eligible original papers, reports, letters to the editors, and case reports published from December 2019 to May 10, 2020. The team identified 20 articles related to this topic. We divided them into articles discussing drug-induced and non-drug-induced changes. Studies reported an increased risk of QTc interval prolongations influenced by different therapies based on chloroquine, hydroxychloroquine, and azithromycin. Although these medications increased risks of severe QTc prolongations, they induced no arrhythmia-related deaths. In the non-drug-induced group, ST-T abnormalities, notably ST elevation, accounted for the most observed ECG finding in the patients with COVID-19, but their relation with myocardial injuries was under dispute. This systematic review suggests that identifying ECG patterns that might be related to COVID-19 is vital. Provided that physicians do not recognize these patterns, they might erroneously risk the lives of their patients. Furthermore, important drug-induced ECG changes provide awareness to the health-care workers on the risks of possible therapies.

7 July 2022
Verified
Journal Article
Open access
Omid DadrasOmid Dadras
Omid Dadras
EMEsmaeil Mehraeen
Esmaeil Mehraeen
AKAmirali Karimi
Amirali Karimi
MTMarcarious M. Tantuoyir
Marcarious M. Tantuoyir
AAArian Afzalian
Arian Afzalian
SSSeyedAhmad SeyedAlinaghi
SeyedAhmad SeyedAlinaghi
Introduction: Knowledge of the safety of vaccines is crucial, both to prevent and cure them and to decrease the public hesitation in receiving vaccines. Therefore, this study aimed to systematically review the adverse events reported for inactivated vaccines and Novavax. Methods: In this systematic review, the databases of PubMed, Scopus, Cochrane, and Web of Science were searched on September 15, 2021. Then we identified the eligible studies using a two-step title/abstract and full-text screening process. Data on the subjects, studies, and types of adverse events were extracted and entered in a word table, including serious, mild, local, and systemic adverse events as well as the timing of side effects' appearance. Results: Adverse effects of inactivated coronavirus vaccines side effects were reported from phases 1, 2, and 3 of the vaccine trials. The most common local side effects included injection site pain and swelling, redness, and pruritus. Meanwhile, fatigue, headache, muscle pain, fever, and gastrointestinal symptoms including abdominal pain and diarrhea were among the most common systemic adverse effects. Conclusion: This systematic review indicates that inactivated COVID-19 vaccines, including Sinovac, Sinopharm, and Bharat Biotech, as well as the protein subunit vaccines (Novavax) can be considered as safe choices due to having milder side effects and fewer severe life-threatening adverse events.

22 October 2022 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
FVFardis Vosoughi
Fardis Vosoughi
RMRangarirai Makuku
Rangarirai Makuku
MTMarcarious M. Tantuoyir
Marcarious M. Tantuoyir
FYFarbod Yousefi
Farbod Yousefi
PSParnian Shobeiri
Parnian Shobeiri
MYMir Saeed Yekaninejad
Mir Saeed Yekaninejad
Background: Several individual studies from specific countries have reported rising numbers of pediatric COVID-19 cases with inconsistent reports on the clinical symptoms including respiratory and gastrointestinal symptoms as well as diverse reports on the mean age and household exposure in children. The epidemiological characteristics of COVID-19 in children are not fully understood, hence, comprehensive meta-analyses are needed to provide a better understanding of these characteristics. Methods: This review was conducted in Medline, Scopus, Cochrane library, Embase, Web of Science, and published reports on COVID-19 in children. Data were extracted by two independent researchers and a third researcher resolved disputes. STATA software and the random-effect model were used in the synthesis of our data. For each model, the heterogeneity between studies was estimated using the Q Cochrane test. Heterogeneity and publication bias were calculated using the I2 statistic and Egger’s/Begg’s tests. Results: The qualitative systematic review was performed on 32 articles. Furthermore, the meta-analysis estimated an overall rate of involvement at 12% (95% CI: 9–15%) among children, with an I2 of 98.36%. The proportion of household exposure was calculated to be 50.99% (95% CI: 20.80%–80.80%) and the proportion of admitted cases was calculated to be 45% (95% CI: 24%–67%). Additionally, the prevalence of cough, fatigue, fever and dyspnea was calculated to be 25% (95% CI: 0.16–0.36), 9% (95% CI: 0.03–0.18), 33% (95% CI: 0.21–0.47) and 9% (95% CI: 0.04–0.15), respectively. It is estimated that 4% (95% CI: 1–8%) of cases required intensive care unit admission. Conclusions: The pediatric clinical picture of COVID-19 is not simply a classic respiratory infection, but unusual presentations have been reported. Given the high incidence of household transmission and atypical clinical presentation in children, we strongly recommend their inclusion in research and population-based preventive measures like vaccination as well as clinical trials to ensure efficacy, safety, and tolerability in this age group.